ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2018

Dec 12, 2018

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bernard Edward Tuch
Date of last notice	13 December 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest	Director
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	13 December 2018
No. of securities held prior to change	36,800 fully paid ordinary shares held in
	the name of DTU Pty Limited ATF The
	Beryl Super Fund
Class	Unlisted Options
Number acquired	600,000 unlisted options
Number disposed	nil
Value/Consideration	Exercisable at $0.0487 per option and
Note: If consideration is non-cash, provide details and estimated valuation	expiring on 13 December 2022.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	36,800 fully paid ordinary shares
	held in the name of DTU Pty Limited ATF
	The Beryl Super Fund
	600,000 unlisted options
	held in the name of DTU Pty Limited ATF
	The Peckham Trust
Nature of change	Following shareholder approval at the
Example: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	annual general meeting held on 15November 2018, Professor Tuch has been
	issued600,000optionsfornil
	consideration with an exercise price of
	$0.0487 with an expiry date of 13
	December 2022. These options comprise
	acomponentoftheDirectors’
	remuneration.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?
If prior written clearance was provided, on what date was thisprovided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3